Nanomultiplex LLC has received the status of a resident of the Skolkovo Innovation Center

The goal of the company, founded as a part of LNBE activities, is to develop a versatile system for multiplexed early diagnosis of cancer and autoimmune diseases, perform preclinical and clinical trials, and commercialize the production of diagnostic preparations. This summer Nanomultiplex LLC has officially become a Skolkovo resident company after receiving the Certificate of registration as a participant in the project on the foundation, launching, and operation of the Skolkovo Innovation Center on July 17, 2013.

The novelty of the diagnostic system designed by the company is that it employs nano–bio hybrid probes that, upon binding with their respective biomarker, are detected by fluorescence of semiconductor nanocrystals (quantum dots) serving as cores of these probes. The system is two orders of magnitude more sensitive compared to commercial analogues available to date. Besides, it allows many different biomarkers to be detected simultaneously because the corresponding capture molecules can be linked to quantum dots that fluoresce in different colors but have the same excitation spectrum. The diagnostic system is based on the results of fundamental and applied research carried out in LNBE.

The nearest plans of Nanomultiplex LLC include close collaboration with Russian and foreign companies manufacturing diagnostic preparations and foundations supporting research and implementation programs.

Contact:

Prof. Igor Nabiev, PhD, DSc., Leading Scientist of LNBE (igor.nabiev@gmail.com),

Leading Scientist of the Laboratory of Nano-Bioengineering, Moscow Engineering Physics Institute, 31 Kashirskoe shosse, 115409 Moscow, Russian Federation
http://www.lnbe.mephi.ru

 
 
 
© 2012 Laboratory of Nano-BioEngineering